A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People
Key facts
- Who runs it
- BioNTech SE
- Where
- Charlottesville, Chesterfield, Hialeah, Honolulu, Houston, Lake Forest, Las Vegas, Mesquite, Miami, Miami Lakes, Milford, Omaha, Orlando, Portsmouth, Salt Lake City, San Diego, Springfield, Stockbridge, Tomball, and Walnut Creek, United StatesSee the 22 sites
- Trial code
- Status
- Completed
- Phase
- Phase 1/2
- People taking part
- 1,353 people enrolled
- Started
- 11 Nov 2024
- Ended
- 15 Jul 2025
- Type of study
- Interventional, 15 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Investigational Influenza Vaccine
- COVID-19 Vaccine
- Investigational Influenza/COVID-19 Vaccine
- Licensed Influenza Vaccine 1
- Licensed Influenza Vaccine 2
- Placebo
- Record updated
- 19 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Participants 18 years of age or older
- Healthy participants who are determined by medical history, physical examination (if clinically required), and clinical judgment of the investigator to be eligible for inclusion in the study
Who cannot take part
- Treated with antiviral therapies for influenza (eg, Tamiflu) within 180 days prior to Day 1; Please refer to the study contact for further eligibility details
- Vaccination with any investigational or licensed 2024-2025 season formulation influenza or COVID-19 vaccine
Where in United States
- Charlottesville Medical ResearchCharlottesville, United States
- Clinical Research ProfessionalsChesterfield, United States
- Indago Research & Health Center, IncHialeah, United States
- East-West Medical Research InstituteHonolulu, United States
- DM Clinical Research- CyfairHouston, United States
- Orange County Research CenterLake Forest, United States
- Las Vegas Clinical TrialsLas Vegas, United States
- SMS Clinical ResearchMesquite, United States
- Miami Dade Medical Research Institute, LLCMiami, United States
- Palm Springs Community Health CenterMiami Lakes, United States
- Clinical Research ConsultingMilford, United States
- Velocity Clinical Research - OmahaOmaha, United States
- Headlands Research OrlandoOrlando, United States
- ActivMed Practices & Research, LLC.Portsmouth, United States
- J. Lewis Research, Inc. / Foothill Family ClinicSalt Lake City, United States
- J. Lewis Research, Inc. / Foothill Family Clinic SouthSalt Lake City, United States
- Artemis Institute for Clinical ResearchSan Diego, United States
- Bio-Kinetic Clinical Applications, LLC dba QPS-MOSpringfield, United States
- Bio-Kinetic Clinical Applications, LLC dba QPS-MO-Screening and Recruitment CenterSpringfield, United States
- Clinical Research AtlantaStockbridge, United States
- Dynamed Clinical Research, LP d/b/a DM Clinical ResearchTomball, United States
- Diablo Clinical Research, Inc.Walnut Creek, United States
About the trial
What the trial wants to find out
This study is to learn about flu and COVID vaccines, either alone or when mixed together. Healthy people aged 18 or older can join. Participants will get one shot in each arm, either a flu or COVID vaccine, alone or mixed. The study lasts about 6 months, and participants need to visit the research site at least 3 times.
The 15 groups in the trial
- Arm A/AATreatment being tested
Low Dose COVID-19 Vaccine and Placebo
Treatment: COVID-19 Vaccine and Placebo
- Arm B/BBTreatment being tested
Medium Dose COVID-19 Vaccine and Placebo
Treatment: COVID-19 Vaccine and Placebo
- Arm C/CCExisting treatment, for comparison
High Dose COVID-19 Vaccine and Placebo
Treatment: COVID-19 Vaccine and Placebo
- Arm D/DDTreatment being tested
Low Dose Investigational Influenza Vaccine and Placebo
Treatment: Investigational Influenza Vaccine and Placebo
- Arm EExisting treatment, for comparison
Licensed Influenza Vaccine 1 and Licensed COVID-19 Vaccine
Treatment: COVID-19 Vaccine and Licensed Influenza Vaccine 1
- Arm EEExisting treatment, for comparison
Licensed Influenza Vaccine 2 and Licensed COVID-19 Vaccine
Treatment: COVID-19 Vaccine and Licensed Influenza Vaccine 2
- Arm F/FFTreatment being tested
Medium Dose Investigational Influenza Vaccine and Placebo
Treatment: Investigational Influenza Vaccine and Placebo
- Arm G/GGTreatment being tested
Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine and Placebo
Treatment: Investigational Influenza/COVID-19 Vaccine and Placebo
- Arm H/HHTreatment being tested
Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine and Placebo
Treatment: Investigational Influenza/COVID-19 Vaccine and Placebo
- Arm I/IITreatment being tested
Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine and Placebo
Treatment: Investigational Influenza/COVID-19 Vaccine and Placebo
- Arm J/JJTreatment being tested
High Dose Investigational Influenza Vaccine and Placebo
Treatment: Investigational Influenza Vaccine and Placebo
- Arm K/KKTreatment being tested
Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine and Placebo
Treatment: Investigational Influenza/COVID-19 Vaccine and Placebo
- Arm L/LLTreatment being tested
Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine and Placebo
Treatment: Investigational Influenza/COVID-19 Vaccine and Placebo
- Arm M/MMTreatment being tested
High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine and Placebo
Treatment: Investigational Influenza/COVID-19 Vaccine and Placebo
- Arm NTreatment being tested
High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine and Placebo
Treatment: Investigational Influenza/COVID-19 Vaccine and Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID-19 IN HEALTHY INDIVIDUALS
- Record updated
- 19 August 2026